StrokeNet Funds its First Pediatric Rehabilitation Phase 3 Clinical Trial

I-ACQUIRE is a Phase III multi-site randomized controlled trial comparing 2 dosages of an intensive pediatric rehabilitation approach known as Infant ACQUIRE (I-ACQUIRE) to Usual and Customary treatment (U&CT) to determine the effect on infant motor behaviors.  Prior studies of this treatment show high safety, patient acceptability, and evidence of significant and enduring benefits.  Briefly, I-ACQUIRE is used to treat 8 – 36 month old children with Perinatal Arterial Ischemic Stroke in either 3 hours/day (Moderate Dose) or 6 hours/day (High Dose) for 5 days/week for 4 weeks.  Treatment occurs in a homelike or natural setting where trained therapists (certified in the I-ACQUIRE protocol) apply operant conditioning techniques to reinforce and shape new and more advanced upper extremity skills through interesting, fun, and everyday games, exploration, and self-help activities.  For each child, treatment goals are set with parents who also participate in daily home practice (about 45 minutes/day) with their child.  I-ACQUIRE includes all of the core features of pediatric Constraint-Induced Movement Therapy (CIMT).  Fidelity of implementing the I-ACQUIRE protocol is monitored regularly via videotaped sessions.  I-ACQUIRE is currently recruiting: for further information, check out the I-ACQUIRE website.